Intellia Therapeutics Names Graeme Bell Chief Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Intellia Therapeutics Names Graeme Bell Chief Financial Officer

CAMBRIDGE, Mass., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA ), a leading genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9 technology, has appointed Graeme Bell as its Chief Financial Officer. Mr. Bell succeeds Sapna Srivastava, Ph.D., who is transitioning to a senior advisory role within Intellia.

Mr. Bell joins Intellia from his role as Chief Financial Officer at Anacor Pharmaceuticals, Inc., a publicly traded biopharmaceutical company acquired by Pfizer, Inc. in June 2016. At Anacor, he led the finance, human resources, business development, IT, and facilities functions. Prior to Anacor, Mr. Bell spent more than 20 years at Merck & Co, Inc., where he held numerous finance and accounting senior-level positions including: CFO of U.S. operations, Controller, Global Pharmaceutical Franchises, CFO United Kingdom subsidiary, and head of investor relations. He is a Fellow of the Institute of Management Accountants with an MBA from the University of Durham, UK. 

Mr. Bell will relocate to Intellia’s headquarters in Cambridge, Massachusetts, overseeing all financial functions including financial planning and analysis, financial reporting, treasury, tax, accounting, and finance. Additionally, Mr. Bell will be responsible for investor relations.

Dr. Srivastava has decided to transition from the Chief Financial and Strategy Officer role to a senior advisor primarily due to her personal commitments in New York City. Dr. Srivastava joined Intellia in April 2015, and played an integral role in helping start up Intellia’s financial operations and strategic direction, the Series B private funding, and the initial public offering. Dr. Srivastava is committed to ensuring a smooth transition of her responsibilities to Mr. Bell. At the conclusion of her advisory role, Dr. Srivastava will transition from Intellia.

“I want to thank Sapna for her significant contributions to ensuring that Intellia’s business strategy and public offering were successful,” said Chief Executive Officer and Founder Nessan Bermingham, Ph.D. “We welcome Graeme to his new role as he joins us for the next phase of growth in our company. We are excited about his extensive financial and operational experience and existing relationships with the investment community.”

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com ; Follow us on Twitter @intelliatweets.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements include, but are not limited to, statements regarding our growth as a company and the anticipated contribution of executives to our operations and progress. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of our product candidates will not be successfully developed and commercialized, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving similar product candidates will not be repeated or observed in ongoing or future studies involving current product candidates, the risk that our collaboration with Novartis or Regeneron will not continue or will not be successful, risks related to the competitive landscape, and risks related to our ability to protect and maintain our intellectual property position. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia Therapeutics undertakes no duty to update this information unless required by law.

Intellia Contacts: Media: Jennifer Mound Smoter Chief External Affairs & Communications Officer +1 857-706-1071 jenn.smoter@intelliatx.com Investors: John Graziano Trout Group + 1 646-378-2942 jgraziano@troutgroup.com Chad Rubin Trout Group + 1 646-378-2947 crubin@troutgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 111

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Kos & FORTH Partner to Spark Greek Biotech Growth

Updated Category News Views 81

New Frontiers: Greece on the Biotech Map Partnerships in biotech aren't tossed out willy-nilly; they're crafted for precision much like a sculptor shaping marble. Kos Biotechnology Partners and the Foundation for Research and Technology-Hellas (FORTH) are doing exactly that, teaming up to birth a biotechnology incubator on the FORTH campus in Heraklion, Crete. Now tell...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 161

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 99

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 210

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
NeuroPace Faces Investigation After Revenue Forecast Cut

Updated Category News Views 35

NeuroPace Revenue Drama: A Blow to Investor Confidence How the mighty have stumbled—or so it feels to the folks who put their bucks into NeuroPace, Inc. (NASDAQ: NPCE). It's tough to swallow: they cut their 2026 revenue forecast from a hopeful $99.5-$101.5 million to a sobering $91-$92 million. Just one quarter apart those projections are, like a cruel twist of fate...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 128

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Investors, Portillo's Fraud Claims Demand Your Attention

Updated Category News Views 71

Portillo's Investors Caught in a Tough Spot Ah, Portillo's. You thought those hot dogs were the only spicy thing you're biting into? Try these allegations on for size. Investors are biting back with a securities fraud lawsuit, and the details are saltier than a bucket of fries. The folks who held PTLO shares between September 19, 2023, and May 4, 2026, are in the...

Continue Reading
Ontario Airport Braces for Holiday Travel Surge

Updated Category News Views 126

Gearing Up for a Thanksgiving Travel Boom Think Thanksgiving brings only turkey to the table? Down in Ontario, California, it's all about jet fuel and passenger counts. The Ontario International Airport (ONT) is where the skies are buzzing, forecasting over 227,000 passengers trying to soak up the holiday vibes by air. Compare that to the numbers when the local folks...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 203

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading

Top 5 Most Recently Viewed Articles

Tesla Faces Sales Challenges in Europe Amidst Controversies

Updated Category News Views 428

Tesla's Declining Sales in Key European Markets Tesla Inc (NASDAQ: TSLA) is facing significant sales declines in several European countries as reported in early 2025. These drops, drastic in some cases, seem to be a reflection of growing consumer dissatisfaction linked to CEO Elon Musk's heightened political involvement. The Impact of Elon Musk's Political Engagement As...

Continue Reading
How CareMessage's Wellness Copilot Enhances Diabetes Care

Updated Category News Views 141

Innovative Solutions for Diabetes Care Enhancement CareMessage, a pioneering non-profit organization, recently introduced the Wellness Copilot aimed at transforming diabetes management for vulnerable populations. The initiative comes at a crucial time when many healthcare systems are struggling to meet the demands of an ever-growing diabetic population across the country....

Continue Reading
MEDIROM Healthcare Technologies Announces Major Public Offering

Updated Category News Views 269

MEDIROM Healthcare Technologies Inc. Pricing Public Offering MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) has announced a significant step forward in its growth strategy by pricing a public offering of American Depositary Shares. This offering involves 2,860,000 shares priced at $1.75 each, totaling gross proceeds of around $5,000,000. The company is anticipating...

Continue Reading
Dreame's LEAPTIC Cube: Revolutionizing Action Cameras Today

Updated Category News Views 201

Dreame Unveils the LEAPTIC Cube: The Future of Action Cameras At CES 2026 in Las Vegas, Dreame Technology proudly introduced the LEAPTIC Cube, the company's first 8K AI action camera. This innovative release signifies a remarkable advancement in portable imaging, tailored for content creators, adventurers, and professionals seeking exceptional performance in a compact...

Continue Reading
Two Hands Corporation's Significant Shareholder Meeting Update

Updated Category News Views 294

Two Hands Corporation Reports on Special Meeting Outcomes Two Hands Corporation (CSE: TWOH.X) (OTC: TWOH) recently held a significant special meeting for its shareholders. This gathering served as a platform to discuss vital changes affecting the company's structure and stock distribution. Highlights from the Special Meeting During the meeting, shareholders voted to...

Continue Reading